Scholarlink

<p>Men having sex with men (MSM) in Cameroon are disproportionately affected by HIV. We evaluated virological response and HIV drug resistance (HIVDR) at a community-based organization between 2022 and 2023. Enhanced adherence counselling (EAC) sessions were conducted for all and cases with unsuppressed viral load (VL &gt; 1000 copies/ml) underwent genotyping. From 502 treatment-experienced MSM enrolled, 95 (18.9%) had unsuppressed VL with 82 (86.3%) accepting to participate (ART-duration: 3 [2–5] years; 95.1% (78/82) under Tenofovir + Lamivudine + Dolutegravir). EAC led to 97.6% (80/82) suppression with 1/2 participant harboring HIVDR. High suppression rates and low HIVDR demonstrate the effectiveness of treatment strategies locally; supporting the possibility of global HIV elimination targets among key populations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Brief communication: virological response and drug resistance patterns among men who have sex with men in Yaoundé-Cameroon

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月9日

查看全文
  • Carine Tadenfok,
  • Joseph Fokam,
  • Ezechiel Ngoufack Jagni Semengue,
  • Antoine Silvère Olongo,
  • Guy Fako,
  • Grace Angong Beloumou,
  • Alex Durand Nka,
  • Desire Takou,
  • Bouba Yagai,
  • Jacques Ateba Ateba,
  • Tanguy Kamgain,
  • Bibiane Ndzié,
  • Francois Badona,
  • Biongolo Emmanuel,
  • Elong Lobe Elise,
  • Ariane Feukeng,
  • David Anouar,
  • Collins Chenwi Ambe,
  • Rogers Ajeh Awoh,
  • Justin Ndie,
  • Anne-Cecile Bissek,
  • Iliassou Njindam,
  • Alexis Ndjolo,
  • Nicaise Ndembi,
  • Carlo-Federico Perno,
  • Celine Nkenfou

摘要

Men having sex with men (MSM) in Cameroon are disproportionately affected by HIV. We evaluated virological response and HIV drug resistance (HIVDR) at a community-based organization between 2022 and 2023. Enhanced adherence counselling (EAC) sessions were conducted for all and cases with unsuppressed viral load (VL > 1000 copies/ml) underwent genotyping. From 502 treatment-experienced MSM enrolled, 95 (18.9%) had unsuppressed VL with 82 (86.3%) accepting to participate (ART-duration: 3 [2–5] years; 95.1% (78/82) under Tenofovir + Lamivudine + Dolutegravir). EAC led to 97.6% (80/82) suppression with 1/2 participant harboring HIVDR. High suppression rates and low HIVDR demonstrate the effectiveness of treatment strategies locally; supporting the possibility of global HIV elimination targets among key populations.